Guidant Wealth Advisors’s AbbVie ABBV Stock Holding History

Guidant Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$358K	Sell	4,724 -142	-3%	-$9.73K	0.13%	86
2019 Q2	$354K	Buy	4,866 +302	+7%	+$23.7K	0.14%	86
2019 Q1	$368K	Buy	4,564 +344	+8%	+$28.1K	0.14%	82
2018 Q4	$389K	Hold	4,220	–	–	0.18%	70
2018 Q3	$400K	Sell	4,220 -51	-1%	-$4.84K	0.17%	34
2018 Q2	$397K	Sell	4,271 -21	-0.5%	-$2.05K	0.17%	33
2018 Q1	$392K	Buy	4,292 +21	+0.5%	+$2.31K	0.18%	33
2017 Q4	$424K	Sell	4,271 -252	-6%	-$23.8K	0.19%	33
2017 Q3	$410K	Buy	4,523 +1,232	+37%	+$93.8K	0.29%	32
2017 Q2	$236K	Buy	3,291 +230	+8%	+$15.5K	0.12%	64
2017 Q1	$198K	Hold	3,061	–	–	0.1%	67
2016 Q4	$187K	Hold	3,061	–	–	0.11%	70
2016 Q3	$193K	Buy	+3,061	New	+$198K	0.12%	64

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Guidant Wealth Advisors's ABBV Position: Q3 2019 in Review

Guidant Wealth Advisors reduced its AbbVie (ABBV) stake by 2.9% in Q3 2019, selling an estimated $9.73K and leaving 4,724 shares worth $358K. The position accounts for 0.13% of the portfolio, ranked #86.

Guidant Wealth Advisors first reported a position in ABBV in Q3 2016 and has held it in 13 quarters since. The position peaked at $424K in Q4 2017. 2,002 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

Guidant Wealth Advisors held 4,724 shares of AbbVie worth $358K as of Q3 2019.
Guidant Wealth Advisors sold 142 AbbVie shares in Q3 2019, an estimated $9.73K.
AbbVie made up 0.13% of Guidant Wealth Advisors's portfolio in Q3 2019, its #86 holding.
Guidant Wealth Advisors first reported a position in AbbVie in Q3 2016 and has held it in 13 quarters since.
Guidant Wealth Advisors's AbbVie position peaked at $424K in Q4 2017.
2,002 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Guidant Wealth Advisors's 13F filing for Q3 2019, filed 16 Oct 2019.